|
ชื่อเรื่อง
|
: |
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates |
|
นักวิจัย
|
: |
Cressey T. , Punyawudho B. , Le Coeur S. , Jourdain G. , Saenjum C. , Capparelli E. , Jittayanun K. , Phanomcheong S. , Luvira A. , Borkird T. , Puangsombat A. , Aarons L. , Sukrakanchana P. , Urien S. , Lallemant M. , Sangsawang S. , Achalapong J. , Preedisripipat K. , Putiyanun C. , Wanchaitanawong V. , Yuthavisuthi P. , Ngampiyaskul C. , Kanjanavikai P. , Chotivanich N. , Hongsiriwon S. , Suwankornsakul W. , Sreshthatat P. , Kanjanasing A. , Kwanchaipanich R. , Rawangban B. , Santadusit S. , Jarupanich T. , Warachit B. , Siriwachirachai T. , Rojanakarin P. , Vivatpatanakul K. , Hanpinitsak S. , Wanasiri P. , Srirojana S. , Kongpanichkul R. , Bunjongpak S. , Sabsanong P. , Liampongsabuddhi P. , Pongdetudom K. , Khamja P. , Akarathum N. , Phonin S. , Limpitikul W. , Jungpipun J. , Petprakorp R. , Mahattanan S. , Kotchawet S. , Pilalai T. |
|
คำค้น
|
: |
- |
|
หน่วยงาน
|
: |
มหาวิทยาลัยเชียงใหม่ |
|
ผู้ร่วมงาน
|
: |
- |
|
ปีพิมพ์
|
: |
2560 |
|
อ้างอิง
|
: |
15254135 , 2-s2.0-85025687300 , 10.1097/QAI.0000000000001447 , https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85025687300&origin=inward , http://cmuir.cmu.ac.th/jspui/handle/6653943832/40175 |
|
ที่มา
|
: |
- |
|
ความเชี่ยวชาญ
|
: |
- |
|
ความสัมพันธ์
|
: |
- |
|
ขอบเขตของเนื้อหา
|
: |
- |
|
บทคัดย่อ/คำอธิบาย
|
: |
© Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Background: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates. Methods: The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with < 8 weeks of antiretroviral treatment before delivery (NCT01511237). Infants received a 2-week course of zidovudine/lamivudine/NVP (NVP syrup/once daily: 2 mg/kg for 7 days; then 4 mg/kg for 7 days). Infant samples were assessed during the first 2 weeks of life. NVP population pharmacokinetics (PK) parameters were estimated using nonlinear mixed-effects models. Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis ( > 0.10 mg/L) and for therapeutic efficacy ( > 3.0 mg/L) using different infant dosing strategies. Results: Sixty infants (55% male) were included. At birth, median (range) weight was 2.9 (2.3-3.6) kg. NVP concentrations were best described by a 1-compartment PK model. Infant weight and postnatal age influenced NVP PK parameters. Based on simulations for a 3-kg infant, ≥92% would have an NVP trough > 0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens. For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough > 3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks. Conclusion: WHO weight-band prophylactic guidelines achieved target concentrations. Starting NVP 6 mg/kg twice daily from birth is expected to achieve therapeutic concentrations during the first 2 weeks of life. |
| บรรณานุกรม |
: |
Cressey T. , Punyawudho B. , Le Coeur S. , Jourdain G. , Saenjum C. , Capparelli E. , Jittayanun K. , Phanomcheong S. , Luvira A. , Borkird T. , Puangsombat A. , Aarons L. , Sukrakanchana P. , Urien S. , Lallemant M. , Sangsawang S. , Achalapong J. , Preedisripipat K. , Putiyanun C. , Wanchaitanawong V. , Yuthavisuthi P. , Ngampiyaskul C. , Kanjanavikai P. , Chotivanich N. , Hongsiriwon S. , Suwankornsakul W. , Sreshthatat P. , Kanjanasing A. , Kwanchaipanich R. , Rawangban B. , Santadusit S. , Jarupanich T. , Warachit B. , Siriwachirachai T. , Rojanakarin P. , Vivatpatanakul K. , Hanpinitsak S. , Wanasiri P. , Srirojana S. , Kongpanichkul R. , Bunjongpak S. , Sabsanong P. , Liampongsabuddhi P. , Pongdetudom K. , Khamja P. , Akarathum N. , Phonin S. , Limpitikul W. , Jungpipun J. , Petprakorp R. , Mahattanan S. , Kotchawet S. , Pilalai T. . (2560). Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Cressey T. , Punyawudho B. , Le Coeur S. , Jourdain G. , Saenjum C. , Capparelli E. , Jittayanun K. , Phanomcheong S. , Luvira A. , Borkird T. , Puangsombat A. , Aarons L. , Sukrakanchana P. , Urien S. , Lallemant M. , Sangsawang S. , Achalapong J. , Preedisripipat K. , Putiyanun C. , Wanchaitanawong V. , Yuthavisuthi P. , Ngampiyaskul C. , Kanjanavikai P. , Chotivanich N. , Hongsiriwon S. , Suwankornsakul W. , Sreshthatat P. , Kanjanasing A. , Kwanchaipanich R. , Rawangban B. , Santadusit S. , Jarupanich T. , Warachit B. , Siriwachirachai T. , Rojanakarin P. , Vivatpatanakul K. , Hanpinitsak S. , Wanasiri P. , Srirojana S. , Kongpanichkul R. , Bunjongpak S. , Sabsanong P. , Liampongsabuddhi P. , Pongdetudom K. , Khamja P. , Akarathum N. , Phonin S. , Limpitikul W. , Jungpipun J. , Petprakorp R. , Mahattanan S. , Kotchawet S. , Pilalai T. . 2560. "Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates". เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Cressey T. , Punyawudho B. , Le Coeur S. , Jourdain G. , Saenjum C. , Capparelli E. , Jittayanun K. , Phanomcheong S. , Luvira A. , Borkird T. , Puangsombat A. , Aarons L. , Sukrakanchana P. , Urien S. , Lallemant M. , Sangsawang S. , Achalapong J. , Preedisripipat K. , Putiyanun C. , Wanchaitanawong V. , Yuthavisuthi P. , Ngampiyaskul C. , Kanjanavikai P. , Chotivanich N. , Hongsiriwon S. , Suwankornsakul W. , Sreshthatat P. , Kanjanasing A. , Kwanchaipanich R. , Rawangban B. , Santadusit S. , Jarupanich T. , Warachit B. , Siriwachirachai T. , Rojanakarin P. , Vivatpatanakul K. , Hanpinitsak S. , Wanasiri P. , Srirojana S. , Kongpanichkul R. , Bunjongpak S. , Sabsanong P. , Liampongsabuddhi P. , Pongdetudom K. , Khamja P. , Akarathum N. , Phonin S. , Limpitikul W. , Jungpipun J. , Petprakorp R. , Mahattanan S. , Kotchawet S. , Pilalai T. . "Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates." เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2560. Print.
Cressey T. , Punyawudho B. , Le Coeur S. , Jourdain G. , Saenjum C. , Capparelli E. , Jittayanun K. , Phanomcheong S. , Luvira A. , Borkird T. , Puangsombat A. , Aarons L. , Sukrakanchana P. , Urien S. , Lallemant M. , Sangsawang S. , Achalapong J. , Preedisripipat K. , Putiyanun C. , Wanchaitanawong V. , Yuthavisuthi P. , Ngampiyaskul C. , Kanjanavikai P. , Chotivanich N. , Hongsiriwon S. , Suwankornsakul W. , Sreshthatat P. , Kanjanasing A. , Kwanchaipanich R. , Rawangban B. , Santadusit S. , Jarupanich T. , Warachit B. , Siriwachirachai T. , Rojanakarin P. , Vivatpatanakul K. , Hanpinitsak S. , Wanasiri P. , Srirojana S. , Kongpanichkul R. , Bunjongpak S. , Sabsanong P. , Liampongsabuddhi P. , Pongdetudom K. , Khamja P. , Akarathum N. , Phonin S. , Limpitikul W. , Jungpipun J. , Petprakorp R. , Mahattanan S. , Kotchawet S. , Pilalai T. . Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2560.
|
